CA3022900A1 - Cannabidiol utilise pour reduire une dose de steroide et pour traiter des maladies inflammatoires et auto-immunes - Google Patents

Cannabidiol utilise pour reduire une dose de steroide et pour traiter des maladies inflammatoires et auto-immunes Download PDF

Info

Publication number
CA3022900A1
CA3022900A1 CA3022900A CA3022900A CA3022900A1 CA 3022900 A1 CA3022900 A1 CA 3022900A1 CA 3022900 A CA3022900 A CA 3022900A CA 3022900 A CA3022900 A CA 3022900A CA 3022900 A1 CA3022900 A1 CA 3022900A1
Authority
CA
Canada
Prior art keywords
steroid
cbd
functional derivative
dose
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3022900A
Other languages
English (en)
Inventor
Moshe YESHURUN
Sari Prutchi SAGIV
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stero Biotechs Ltd
Original Assignee
Stero Biotechs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/143,694 external-priority patent/US9889100B2/en
Application filed by Stero Biotechs Ltd filed Critical Stero Biotechs Ltd
Publication of CA3022900A1 publication Critical patent/CA3022900A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

L'invention concerne des méthodes de prévention, d'amélioration et de traitement des effets secondaires des stéroïdes, des états réfractaires aux stéroïdes, des maladies auto-immunes et de l'inflammation du foie à l'aide de cannabidiol et d'une composition de stéroïde.
CA3022900A 2016-05-02 2017-05-01 Cannabidiol utilise pour reduire une dose de steroide et pour traiter des maladies inflammatoires et auto-immunes Pending CA3022900A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/143,694 US9889100B2 (en) 2013-05-02 2016-05-02 Cannabidiol for treatment of severe and refractory graft-versus-host disease
US15/143,694 2016-05-02
PCT/IL2017/050483 WO2017191630A1 (fr) 2016-05-02 2017-05-01 Cannabidiol utilisé pour réduire une dose de stéroïde et pour traiter des maladies inflammatoires et auto-immunes

Publications (1)

Publication Number Publication Date
CA3022900A1 true CA3022900A1 (fr) 2017-11-09

Family

ID=60203614

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3022900A Pending CA3022900A1 (fr) 2016-05-02 2017-05-01 Cannabidiol utilise pour reduire une dose de steroide et pour traiter des maladies inflammatoires et auto-immunes

Country Status (7)

Country Link
EP (1) EP3452046A4 (fr)
KR (1) KR102537990B1 (fr)
CN (2) CN109414443A (fr)
AU (1) AU2017260873B2 (fr)
CA (1) CA3022900A1 (fr)
IL (1) IL262713B1 (fr)
WO (1) WO2017191630A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114727960A (zh) 2019-10-03 2022-07-08 耶路撒冷希伯来大学伊森姆研究发展有限公司 数个脂质体大麻素及其用途
US20230012268A1 (en) * 2019-12-13 2023-01-12 Buzzelet Development And Technologies Ltd. Compositions and methods for treatment of inflammation with steroids and a modulator
WO2021165992A1 (fr) * 2020-02-19 2021-08-26 DR. MERCHANT, Shreema Compositions et utilisations thérapeutiques de cannabidiol
AU2021337234A1 (en) * 2020-09-06 2023-04-20 Medicane Research & Development Ltd Composition comprising cannabinoids, and/or terpens, and methods of using same
CN113398104B (zh) * 2021-07-14 2022-04-08 北京森宏健康科技有限公司 大麻二酚在治疗胆红素脑病中的用途
WO2023058016A1 (fr) * 2021-10-04 2023-04-13 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Institute) Médicaments anti-inflammatoires non stéroïdiens et cannabinoïdes et leurs utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1189603A2 (fr) * 1999-03-22 2002-03-27 Immugen Pharmaceuticals, Inc. Traitement de maladies immunitaires
US20070060638A1 (en) * 2005-08-26 2007-03-15 Olmstead Mary C Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
US8242178B2 (en) * 2007-06-18 2012-08-14 University Of South Carolina Use of cannabidiol in the treatment of autoimmune hepatitis
EP2309858A4 (fr) * 2008-07-31 2011-09-14 Dekel Pharmaceuticals Ltd Compositions et procédés de traitement de troubles inflammatoires

Also Published As

Publication number Publication date
KR20190016952A (ko) 2019-02-19
CN109414443A (zh) 2019-03-01
AU2017260873A1 (en) 2018-11-29
WO2017191630A1 (fr) 2017-11-09
EP3452046A1 (fr) 2019-03-13
KR102537990B1 (ko) 2023-05-30
EP3452046A4 (fr) 2020-02-19
AU2017260873B2 (en) 2023-03-02
IL262713B1 (en) 2024-03-01
CN117017998A (zh) 2023-11-10
IL262713A (en) 2018-12-31

Similar Documents

Publication Publication Date Title
AU2017260873B2 (en) Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases
US20220184057A1 (en) Combination treatment of ocular inflammatory disorders and diseases
US10660865B2 (en) Cannabidiol for the prevention and treatment of graft-versus-host disease
US11357740B2 (en) Cannabidiol for enhancing the therapeutic effect of a steroid
CN113274342B (zh) 一种秋水仙碱外用组合物
WO2013026557A1 (fr) Agent de polythérapie contenant des vasoconstricteurs
US20080262079A1 (en) Cannabinoid Compositions and Methods of Use Thereof
EP0277352A1 (fr) Association synergétique d'azélastine et de théophylline ou d'azélastine et de bêta-mimétiques
US20080262071A1 (en) Pindolol for the Treating Premenstrual Syndrome and Premenstrual Dysphoric Disorder
US20220362230A1 (en) Use of glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling
EP2808025B1 (fr) Composition pharmaceutique et produit cosmétique quasi-médicamenteux utilisant celle-ci
JPWO2006041121A1 (ja) 慢性皮膚疾患の治療および／または予防剤
RU2776878C1 (ru) Способ комбинированного лечения клещевого риккетсиоза, обусловленного Хейлунцзянской риккетсией, органическим селеном
Ponticelli et al. The pharmacology of old and new agents for specific therapy of primary glomerular diseases
US20240024328A1 (en) Ruxolitinib for the treatment of prurigo nodularis
US20240075040A1 (en) Ruxolitinib for the treatment of prurigo nodularis
US20140378426A1 (en) Methods and compositions for enhancing visual function
CN114515293A (zh) 一种毛蕊花糖苷在制备治疗雄激素性脱发药物中的应用
US20220265574A1 (en) Methods of using cannabidiol and a steroid
EA043839B1 (ru) Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
KR20010032771A (ko) 크로모글릭산 화합물의 의약 용도

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220502

EEER Examination request

Effective date: 20220502

EEER Examination request

Effective date: 20220502

EEER Examination request

Effective date: 20220502

EEER Examination request

Effective date: 20220502

EEER Examination request

Effective date: 20220502

EEER Examination request

Effective date: 20220502